张楚怡,李文倩

免疫性血小板减少症属于自身免疫综合征范畴，在其病程的发生与发展过程中，体液免疫反应扮演着关键角色。因此，传统治疗中，针对体液免疫的糖皮质激素、脾切除等疗法成为该病症的优选治疗方案。但近年来，研究发现T细胞、补体等系统也参与了该病的发生发展。本文旨在综述B细胞在免疫性血小板减少症发病机制中的作用，以及新兴靶向治疗的研究进展。

免疫性血小板减少性紫癜；靶向治疗；联合治疗

[1] Alrakha A,Kamal N,Sherif W,et al.Immune Thrombocytopenia Induced by Helicobacter pylori Infection:A Case Report and Literature Review[J].Cureus,2025,17(4):e82167. [2] Terrell D R,Beebe L A,Vesely S K,et al.The incidence of immune thrombocytopenic purpura in children and adults:A critical review of published reports[J].Am J Hematol,2010,85(3):174-180. [3] Bussel J B,Soff G,Balduzzi A,et al.A Review of Romiplostim Mechanism of Action and Clinical Applicability[J].Drug Des Devel Ther,2021,15:2243-2268. [4] George J N.Sequence of treatments for adults with primary immune thrombocytopenia[J].Am J Hematol,2012,87 Suppl 1:S12-S15. [5] Ghanima W,Cooper N,Rodeghiero F,et al.Thrombopoietin receptor agonists:ten years later[J].Haematologica,2019,104(6):1112-1123. [6] Zhou H,Zhou J,Wu D,et al.Romiplostim in primary immune thrombocytopenia that is persistent or chronic:phase III multicenter,randomized,placebo-controlled clinical trial in China[J].Res Pract Thromb Haemost,2023,7(5):100192. [7] Chiang-Wong H,Gonzalez-Saldana P.Romiplostim use in immune thrombocytopenia:Experience in Cuenca,Ecuador[J]. Biomedica, 2024,44(Sp.1):198-204. [8] Wong R,Saleh M N,Khelif A,et al.Safety and efficacy of long-term treatment of chronic/persistent ITP with eltrombopag:final results of the EXTEND study[J].Blood,2017,130(23):2527-2536. [9] Broome C.Efgartigimod alfa for the treatment of primary immune thrombocytopenia[J].Ther Adv Hematol,2023,14:1564090591. [10] Newland A C,Sanchez-Gonzalez B,Rejto L,et al.Phase 2 study of efgartigimod,a novel FcRn antagonist,in adult patients with primary immune thrombocytopenia[J].Am J Hematol,2020,95(2):178-187. [11] Roeser A,Lazarus A H,Mahevas M.B cells and antibodies in refractory immune thrombocytopenia[J].Br J Haematol,2023, 203(1):43-53. [12] Langrish C L,Bradshaw J M,Francesco M R,et al.Preclinical Efficacy and Anti-Inflammatory Mechanisms of Action of the Bruton Tyrosine Kinase Inhibitor Rilzabrutinib for Immune-Mediated Disease[J].J Immunol,2021,206(7):1454-1468. [13] Paik J.Fostamatinib:A Review in Chronic Immune Thrombocytopenia[J].Drugs,2021,81(8):935-943. [14] Gonzalez-Lopez T J,Bermejo-Vega N,Cardesa-Cabrera R,et al.Fostamatinib effectiveness and safety for immune thrombocytopenia in clinical practice[J].Blood,2024,144(6):646-656. [15] Zhang J,Ruan Y,Shen Y,et al.Low dose IL-2 increase regulatory T cells and elevate platelets in a patient with immune thrombocytopenia[J].Cytometry B Clin Cytom,2018,94(3):400-404. [16] Moulinet T,Moussu A,Pierson L,et al.The many facets of immune-mediated thrombocytopenia:Principles of immunobiology and immunotherapy[J].Blood Rev,2024,63:101141. [17] Han F,Jiang Z,Guo Q,et al.CD19 chimeric antigen receptor-T cell therapy in murine immune thrombocytopenia[J].Br J Haematol, 2025,206(5):1430-1442.

点击下载PDF